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OBJECTIVES We used acetylsalicylic acid (ASA) as a probing agent to quantify hydroxyl radical (˙OH) in
Controls and patients with coronary artery disease and to prospectively investigate ˙OH
production in patients with myocardial infarction (MI) complicated by heart failure (HF).
BACKGROUND Oxidative stress status (OSS) is a mechanism for transition to HF in experimental heart injury
models, but evidence for its causal role in humans is still limited.
METHODS Thirty healthy subjects (Controls), 12 patients with stable angina (Group 1), and 74 patients
with ST-segment elevation MI (Group 2) were enrolled. A dose of 250 mg Flectadol was
given intravenously before each blood collection to determine the 2,3-dihydroxybenzoic
acid/salicylic acid (DHBA/SA) ratio. We also quantified vitamin E and coenzyme Q10 to
monitor antioxidant reserve, as well as tumor necrosis factor (TNF)-alpha, TNF-soluble
receptors, interleukin (IL)-6, and IL-1ra to assess inflammatory status. All measurements
were repeated at month 6 in Group 2.
RESULTS There were no differences between Controls and Group 1. Group 2 showed increased ˙OH
production, peaking at 24 h, whereas vitamin E and coenzyme Q10 progressively declined.
Group 2 patients developing HF during hospitalization (Group 2Bi) presented with an
increase of both ˙OH production at discharge and inflammatory status, as compared with
patients without HF (Group 2Ai), persisting at month 6 in post-MI patients with HF
(Group 2Bii).
CONCLUSIONS We found a distinct pattern of ˙OH generation in post-MI patients who show progression to
HF. The interplay between OSS and inflammatory status should be targeted as a possible
mechanism of progression to post-MI left ventricular dysfunction. (J Am Coll Cardiol
2004;43:2000–8) © 2004 by the American College of Cardiology Foundation2
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in imbalance of oxidative stress status (OSS) has been
eported to occur in acute coronary syndromes and heart
ailure (HF) (1). Elevation of reactive oxygen species (ROS)
uring myocardial ischemia occurs both at an early stage—
uring reperfusion (2), contributing to stunning (3,4) and
eperfusion injury (5,6)—and at a late phase—days or weeks
fter myocardial infarction (MI) (7). Experimental studies
ave shown that ROS production at this later stage is
onvincingly associated with post-MI left ventricular (LV)
emodeling and progression to HF (8–11).
An increase of lipid peroxidation markers and encroachment
n antioxidant reserves in chronic HF have been widely
eported in humans (12–14), but no prospective data are
urrently available on the association between (increased) OSS
nd progression to HF in post-MI patients (15).
A radical probing technique for in vivo OSS measurement,
ased on the ability of hydroxyl radical (˙OH) to attack the
enzene ring of aromatic molecules, such as acetylsalicylic acid
ASA), and to produce hydroxylated compounds, such as
From the *Chair of Cardiology, University of Ferrara, Ferrara; †Cardiovascular
esearch Centre, Salvatore Maugeri Foundation, Gussago (Brescia); and ‡Depart-
ent of Pharmacology, Alma Mater Studiorum, University of Bologna, Bologna,
taly. This work was partially supported by a grant from MIUR ex 40% and ex 60%
ntitled “Link between cytokines, apoptosis, and hypertrophy during ventricular and
ascular remodeling.”Manuscript received December 16, 2003; accepted January 7, 2004.,3-dihydroxybenzoic acid (DHBA), has been previously em-
loyed in humans (Fig. 1) (16,17). This method seems
articularly interesting in patients with coronary artery disease,
n whom ASA is indicated for primary and secondary preven-
ion of acute cardiovascular events (18).
We aimed to prospectively investigate the pattern of ˙OH
levation in MI patients with and without transition to HF
y using a recommended intravenous dose of ASA (19) as a
robe for ˙OH production in vivo. Healthy subjects and
table patients with coronary artery disease were similarly
nvestigated.
Endogenous antioxidant molecules—vitamin E and co-
nzyme Q10—and inflammatory status—tumor necrosis
actor (TNF)-alpha, related soluble receptors of tumor
ecrosis factor-alpha (sTNFR), interleukin (IL)-6, and
L-1ra—were also monitored.
ETHODS
tudy population. Thirty healthy subjects and 86 patients
ere enrolled. Their clinical and biochemical profiles are
resented in Table 1. The local Ethics Committee on
uman Research approved the study protocol, and all
articipants gave their written, informed consent to partic-
pate in the study.Three groups were considered: Controls comprised 30
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June 2, 2004:2000–8 Oxidative Stress Status and Post-MI HFealthy subjects who were matched in terms of gender and
ge (19 men; mean age 65  6 years) to the patients. None
ad clinical signs of acute or chronic illness or was receiving
ny treatment. Group 1 comprised 12 patients (8 men; mean
ge 68  11 years) with angiographically documented
oronary atherosclerotic lesions and stable angina (Canadian
ardiovascular Society classes II and III). They were treated
ith beta-blockers (n  11), statins (n  12), angiotensin-
onverting enzyme (ACE) inhibitors (n  9), and calcium
hannel blockers (n 5). Group 2 comprised 74 patients (49
en; mean age 67  10 years) consecutively admitted for
cute MI, defined as the occurrence of typical chest pain at
est lasting 20 min, accompanied by persistent ST-
egment elevation of 1 mm in at least two standard
lectrocardiographic leads or 2 mm in at least two con-
iguous precordial leads. In all Group 2 patients, MI was
Abbreviations and Acronyms
ASA  acetylsalicylic acid
DHBA  dihydroxybenzoic acid
HF  heart failure
IL  interleukin
LV  left ventricular
MI  myocardial infarction
˙OH  hydroxyl radical
OSS  oxidative stress status
ROS  reactive oxygen species
SA  salicylic acid
sTNFR  related soluble receptors of tumor necrosis
factor-alpha
TNF  tumor necrosis factor
igure 1. Oxidative metabolism of salicylic acid: acetylsalicylic acid (ASA)
s rapidly hydrolyzed to SA by esterases and for 60% remains unmodified
nd can undergo hydroxyl radical (˙OH) attack to produce two derivates—
amely, 2,3-dihydroxybenzoic acid (DHBA) and 2,5-DHBA. Enzymatic
athways through the cytochrome P-450 system can also produce the latter
cid, whereas the former acid is solely formed by direct ˙OH attack.
herefore, measurement of 2,3-DHBA or the 2,3-DHBA/SA ratio, after
dministration of ASA, is recognized as a sensitive and specific method to
cetermine ˙OH production in vivo.onfirmed by a rise in serum creatine kinase by twofold or
ore than the upper normal limit during hospitalization.
Exclusion criteria were symptoms lasting 12 h before
ospitalization, history of HF before hospitalization, pres-
nce of any known neoplastic disease, diseases affecting the
mmune system, and ongoing infectious diseases. The in-
arct location was anterior in 36 patients. Fifty-five patients
74%) received accelerated tissue plasminogen activator. All
roup 2 patients were receiving a standard regimen of
eta-blocker, statin, and ACE inhibitor.
The occurrence of HF was defined as the presence of rest
r effort dyspnea and at least one of the following: pulmo-
ary rales at lung auscultation, evidence of pulmonary
ongestion on the chest X-ray, new appearance of peripheral
dema, and use of diuretics.
lood processing. PLASMA. Antecubital venous blood was
ollected in K3 EDTA-containing tubes, immediately cen-
rifuged at 1,700g at 4°C for 15 min, and subsequently
tored at 80°C. Plasma vials that would be used to
easure 2,3-DHBA/SA were also frozen in liquid nitrogen
efore storage.
ERUM. Antecubital venous blood was collected in empty
ubes and, after 45 min, centrifuged at 1,700g at 4°C for 15
in. The serum obtained was stored at 80°C.
OH probing in vivo. The principle behind ˙OH quanti-
cation is schematically shown in Figure 1 (16,17). A dose
f 250 mg Flectadol was given intravenously 5 min before
ach blood collection. The time lag between Flectadol
dministration and blood collection was chosen after pilot
bservations in patients (n  13) or Controls (n  10),
howing no significant changes in the 2,3-DHBA/SA ratio
n the range of 3 to 20 min.
The kinetics of ˙OH production was established in five
ontrols, all Group 1 patients, and 10 Group 2 patients by
ampling at 6, 12, 24, 36, 48, and 72 h after symptom onset
nd then after 5 and 7 days and at discharge (9  3 days).
ased on the results obtained, the remaining 25 Controls
nd 64 Group 2 patients were studied at entry and at 24, 48,
nd 72 h after symptom onset and at discharge (10  4
ays).
xtraction and quantification of 2,3-DHBA and 2,5-
HBA. Aliquots of standard solutions or plasma samples
500 l) were mixed with 20 l of 5 mol/l 3,4-DHBA
internal standard) and acidified with 25 l of concentrated
Cl (37%) in glass tubes. The samples were vortexed for 1
in and centrifuged at 2,000 g for 15 min. Ether (%ml) was
dded to the supernatant. The samples were vortexed for 1
in and centrifuged at 2,000g for 15 min. The ether phase
as extracted. The extraction was repeated (with 3 ml of
ther), and the ether phases were recollected. The ether
hase was then dried under nitrogen steam. The dry residue
as reconstituted in 500 l of mobile phase and filtered on
.22-m filters (Millipore USA), and 100 l was injected
nto the column (XTerra RP18—3.5 m, 4.6  150-mm
artridge columns; Waters, Milford, Massachusetts). Chro-
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Oxidative Stress Status and Post-MI HF June 2, 2004:2000–8atographic separations were performed using a system
onsisting of a high-pressure pump (Waters Model 590,
ultisolvent Delivery System) with an auto sampler (Wa-
ers Model 717 plus) and electrochemical detector (ESA
oulochem II 5200A with High Sensitivity Analytical Cell
odel 5011) connected to an integrator (Millennium32,
hromatography Manager). The mobile phase consisted of
0 mmol/l of citric acid and sodium acetate at pH 3.0
MeOH 20%) each. The flow rate was 0.5 ml/min, and the
nalytical cell potential applied is 250 mV (CH1). The
oncentration of metabolites was determined by the ratio of
espective metabolite peak areas to 3,4-DHBA (internal
tandard).
xtraction and quantification of salicylic acid (SA).
liquots of standard solutions or plasma samples (100 l)
ere mixed with 100 l of 100 mol/l of 2,6-DHBA
internal standard) and deproteinated by 200 l of EtOH in
.5-ml polypropylene conical Eppendorf micro test tubes.
he samples were vortexed for 2 min and centrifuged at
,600 g for 15 min. A total of 200 l of supernatant was
iluted with 200 l of mobile phase. The diluted solution
as then filtered on 0.22-m filters (Millipore), and 50 l
f solution was injected into the column (NovaPak
18—60 Å, 4 m, 3.9 150-mm cartridge columns made
y Waters). Chromatographic separations were performed
sing a system consisting of a high-pressure pump (Waters
odel 600E, Multisolvent Delivery System), a sample
njection valve (Rheodyne Model 7725, Cotati, California)
Table 1. Baseline Characteristics of the Study
Variables
Contro
(n  3
Age (yrs) 65 
Gender (M/F) 19/1
Smokers (Y/N) 16/1
Hypertension (Y/N) 0/30
Family history of CVD (Y/N) 13/1
Hypercholesterolemia (Y/N) 0/30
Diabetes (Y/N) 0/30
LDL cholesterol (mg/dl) 132 
HDL cholesterol (mg/dl) 43 
TG (mg/dl) 109 
Previous MI (Y/N) 0/30
Previous PCI or CABG (Y/N) 0/30
Killip class 1 at entry (%) —
CK peak (U/l) —
CK-MB peak (ng/ml) —
Troponin I (ng/ml) peak —
CRP at entry (mg/dl) —
WBC at entry (103/mm3) —
Hemoglobin (g/dl) —
Glycemia at entry (mg/dl) —
LV ejection fraction (%) —
End-diastolic volume (ml/m2) —
*Healthy volunteers. †Patients with stable angina. ‡Patients
value  SD or number of subjects.
CABG coronary artery bypass grafting; CK creatine k
protein; CVD  cardiovascular disease; HDL  high-de
ventricular; MI  myocardial infarction; N  no; PCI  per
 triglycerides; Y  yes.ith a 50-l sample loop, and a photodiode array detector lWaters Model 996) connected to an integrator (Millenni-
m32, Chromatography Manager). The mobile phase con-
isted of 30 mmol/l each of sodium citrate and acetate at pH
.0 (MeOH 15%). The flow rate was 1 ml/min, and
etection was at 296 nm. The concentration of metabolites
as determined by the ratio of respective metabolite peak
reas to 2,6-DHBA (internal standard).
The ratio of 2,3-DHBA (pmol/l) to SA (nmol/l) is
xpressed as molar ratio  1,000.
lasma levels of vitamin E and coenzyme Q10. Vitamin E
nd coenzyme Q10 were measured by reverse-phase high-
ressure liquid chromatography (HPLC) with wavelength-
rogrammed, ultraviolet-visible absorbance detection (20).
erum triglycerides and total and high-density lipoprotein
holesterol were measured by standard enzymatic colorimet-
ic methods. Low-density lipoprotein cholesterol was cal-
ulated with the Friedewald formula. Vitamin E levels were
xpressed both as an absolute figure and after adjustment for
otal cholesterol. Because vitamin E plasma levels, unlike
oenzyme Q, are modified by diet (21), patients and
ontrols were submitted to a standardized diet for vitamin E
ntake (30 IU/day) during hospitalization and for the entire
eriod of follow-up.
ytokines and cytokine receptor levels. Levels of TNF-
lpha, sTNFR-I, sTNFR-II, IL-6, and IL-1ra were mea-
ured in serum from patients and controls, as previously
escribed (22,23).
ollow-up phase. Group 2 patients were clinically fol-
lation
Group 1†
(n  12)
Group 2‡
(n  74)
68  11 67  10
8/4 49/25
5/7 54/20
10/2 48/26
10/2 36/38
8/4 43/31
5/7 28/46
123  41 146  34
41  12 47  9
121  23 111  50
0/12 9/65
0/12 5/69
0 16
— 3,026  1,276
— 369  209
— 149  201
0.7  0.2 3.4  4
7.1  3.3 10.3  4
14  1.1 13  1.7
111  19 129  40
59  8 48  15
78  19 94  9
cute myocardial infarction. Data are presented as the mean
CK-MB creatine kinase-MB fraction; CRP C-reactive
lipoprotein; LDL  low-density lipoprotein; LV  left
ous coronary intervention; WBC  white blood count; TGPopu
ls*
0)
6
1
4
7
21
9
47
with a
inase;
nsity
cutaneowed after discharge, and at six months, ˙OH probing,
F
m
2
p
o
2003JACC Vol. 43, No. 11, 2004 Valgimigli et al.
June 2, 2004:2000–8 Oxidative Stress Status and Post-MI HFigure 2. Hydroxyl radical generation during the hospital phase. (A) Time course of 2,3-dihydroxybenzoic acid (DHBA)/salicylic acid (SA) (expressed as
olar ratio  1,000) in 10 patients with myocardial infarction (Group 2), all patients with stable angina (Group 1), and 5 Controls. (B) Time course of
,3-DHBA/SA (expressed as molar ratio  1,000) in the remaining 65 patients with myocardial infarction (Group 2) and 25 Controls. Sampling was
erformed at entry (within 12 h from symptom onset), at 24, 48, and 72 h after symptom onset, and at discharge (10 4 days). The insert shows the pattern
f 2,3-DHBA/SA in patients without (Group 2Ai) and with (Group 2Bi) HF during hospitalization.
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Oxidative Stress Status and Post-MI HF June 2, 2004:2000–8itamin E, coenzyme Q10, and inflammatory status mea-
urements were repeated.
hemicals. Sodium SA, sodium citrate, sodium acetate,
itric acid, 2,3-DHBA, 2,5-DHBA, 2.6-DHBA, and 3,4-
HBA were purchased from Sigma (St. Louis, Missouri),
nd HPLC-grade water and methanol were from Labscan
td. (Dublin, Ireland). All others chemicals and solvents
sed were of the highest purity commercially available.
tatistical analysis. Data are expressed as the mean value
SD. Comparisons between two groups were performed
ith the Student t test or the Mann-Whitney U test for
onparametric variables. The Fisher exact test was used for
ategorical variables. Comparisons between more than two
roups were performed by two-tailed analysis of variance,
nd post hoc comparisons were made using the Turkey’s
onest significance difference test. Correlations between
ariables were tested by Pearson analysis. Statistical signif-
cance was set at a level of p  0.05 (Statistica version 6.0).
ESULTS
he baseline characteristics of the study population are
hown in Table 1. Two patients in Group 2 (3%) died of
ntracranial hemorrhage and LV free wall rupture on days 2
nd 3 of hospitalization, respectively; 24 (32%) presented
ith signs and symptoms of HF, 4 (5%) had re-infarction,
nd 3 (4%) showed acute pericarditis.
eneration of ˙OH. The kinetics of ˙OH production is
hown in Figure 2A. No complication occurred in the 10
roup 2 patients enrolled in this analysis. The 2,3-
HBA/SA ratio did not differ between Controls and
roup 1 patients. In Group 2 patients, 2,3-DHBA/SA was
lready significantly higher at entry (0.6  0.1 vs. 0.16 
.06 in Group 1 and 0.17  0.04 in Controls, p  0.05 for
oth), with a peak at 24 h (0.74  0.18 vs. 0.17  0.07 in
roup 1 and 0.18  0.06 in Controls, p  0.001 for both),
ollowed by a decline. Five days after the onset of symptoms,
,3-DHBA/SA returned to normal values (0.28  0.1 vs.
.16  0.08 in Group 1 and 0.15  0.07 in Controls, p 
.09 and p  0.07, respectively).
Based on these data, in the remaining study population,
e limited sampling to the timing reported in Figure 2B.
he 2,3-DHBA/SA ratio was significantly elevated in
roup 2 at entry (0.4  0.09 vs. 0.24  0.04 in Controls,
 0.05), with a peak after 24 h (0.72  0.15 vs. 0.23 
.05 in Controls, p  0.01). Contrary to the data reported
n Figure 2A, increasing the sample size from 10 to 64
esulted in a significant difference in ˙OH production
etween Group 2 and Controls, even at discharge. In Group
, the 2,3-DHBA/SA ratio failed to correlate with the peak
evels of troponin I or creatine kinase, MB fraction and
-reactive protein.
lasma levels of antioxidants. Figure 3 shows plasma
evels of vitamin E (Fig. 3A) and coenzyme Q10 (Fig. 3B).
evels of both these antioxidants did not change in Group
and Controls throughout the study. On the other hand, coth antioxidant compounds showed a progressive decline
n Group 2 patients. Vitamin E levels were significantly
ecreased 24 h after symptom onset (27  5 vs. 39  2.3
mol/l in Controls, p  0.05), with a further decline
hereafter. Coenzyme Q10 decreased significantly at dis-
harge (0.9  0.3 vs. 1.7  0.5 g/ml in Controls, p 
.05).
ole of HF. The different patterns of ˙OH production in
roup 2 patients with respect to the absence (Group 2Ai)
r presence (Group 2Bi) of HF during hospitalization are
hown in the insert of Figure 2B. Group 2Bi patients tended
o maintain a higher degree of ˙OH production after the
eak at 24 h, which became significant at discharge. In
ontrast, as shown in Table 2, the degree of antioxidant
onsumption was not different between Groups 2Ai and
Bi, either considered as the absolute difference or percent-
ge of decrease.
ytokines and cytokine receptor levels. Cytokines and
ytokine receptor levels are reported in Table 3. All tested
igure 3. Levels of vitamin E and coenzyme Q10 during the hospital phase.
ime course of vitamin E (A) and coenzyme Q10 (B) levels in Controls (n
30; open circles), patients with stable angina (Group 1, n  12;
nverted triangles), and patients with myocardial infarction (Group 2, n
4; solid circles). Sampling times were at entry, 24, 48, and 72 h after
ymptom onset, and at discharge. *p  0.05 versus Group 2. †p  0.01
ersus Group 2.ytokines were significantly increased in Group 2 compared
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June 2, 2004:2000–8 Oxidative Stress Status and Post-MI HFith Group 1 patients and Controls. All tested cytokines
ere significantly elevated in Group 2Bi versus Group 2Ai
TNF-alpha: 34  16 pg/ml vs. 24  7 pg/ml, p  0.0001;
TNFR-I: 2,235  1,132 pg/ml vs. 1,518  702 pg/ml, p
0.0001; sTNFR-II: 3,185 1,420 pg/ml vs. 2,222 914
g/ml, p 0.0001; IL-6: 41 42 pg/ml vs. 14 19 pg/ml,
 0.0001; IL-1ra: 1,294  888 pg/ml vs. 966  685
g/ml, p  0.04, respectively). Group 2 patients with high
above median value), compared with those with low levels
f TNF-alpha, sTNFR-I, and sTNFR-II, showed a signif-
cant increase of 2,3-DHBA/SA levels at discharge (Fig. 4).
orrelations. The percentage of vitamin E decrease during
ospitalization was significantly related to that of coenzyme
10 decrease (r  0.61, p  0.05). The percentage of
itamin E decrease correlated significantly with 2,3-
HBA/SA at 24-h peak (r  0.54, p  0.05).
ollow-up phase. During follow-up, three patients died; at
ix months, 15 patients presented with signs/symptoms of
F (10 patients were in New York Heart Association
unctional class II and the remaining 5 were in class III).
he mean 2,3-DHBA/SA ratio was significantly lower in
atients without (Group 2Aii, n  54) than those with
Group 2Bii, n  15) HF (0.23  0.08 vs. 0.43  0.1,
espectively; p 0.0001) (Fig. 5). Vitamin E and coenzyme
10 levels were not different between Group 2Bii and
roup 2Aii patients (32  5 g/ml vs. 37  4 mol/l, p 
.1; 1.2  0.3 g/ml vs. 1.6  0.4 g/ml, respectively; p 
.7).
Levels of TNF-alpha, sTNFR-I, and sTNFR-II were
levated in Group 2Bii compared with Group 2Aii (43 19
g/ml vs. 32  11 pg/ml, p  0.04; 2,940  1,108 pg/ml
s. 2,192  879 pg/ml, p  0.01; and 3,708  1,756 pg/ml
s. 2,978  1,013 pg/ml, p  0.01, respectively). As during
he hospital phase, Group 2 patients with high (above
able 2. Antioxidant Consumption in Patients With Acute Myo
Variables
All
Entry Discharge
itamin E (mol/l) 29  6 20  5*
itamin E/cholesterol (mmol/mol) 5.2  1.3 3.9  1.1*
oenzyme Q10 (g/ml) 1.5  0.5 0.9  0.3*
p  0.05 discharge versus entry. Data are presented as the mean value  SD. Vit
ischarge with respect to hospital admission levels. The degree of antioxidant consum
eart failure during hospitalization.
able 3. Cytokines in the Study Population
Variables
Controls
(n  30)
Group 1
(n  12)
NF-alpha (pg/ml) 18  4 22.5  9
TNFR-I (pg/ml) 978  775 1,297  985
TNFR-II (pg/ml) 1,957  1,403 2,489  1,413
L-6 (pg/ml) 4.3  7 3.4  15
L-1ra (pg/ml) 224  112 306  237
Controls versus Group 2. †Group 1 versus Group 2. ‡Controls versus Group 1. §Ma
ith Group 1 and controls. Data are presented as the mean value  SD. Refer to T
IL-1ra  interleukin 1ra; IL-6  interleukin-6; sTNFR-I  soluble tumor necr
NF-alpha  tumor necrosis factor-alpha.edian value) versus low levels of TNF-alpha, sTNFR-I,
nd sTNFR-II showed a significant increase of the 2,3-
HBA/SA ratios (0.61  0.12 vs. 0.41  0.9, p  0.03;
.65  0.19 vs. 0.39  0.12, p  0.01; 0.66  2 vs. 0.33 
.6, p  0.01, respectively).
ISCUSSION
n vivo measurement of highly reactive free radicals, such as
OH, in humans is difficult. Consequently, secondary prod-
cts of oxidative stress have been measured (24,25), the
ost common being thiobarbituric acid test, conjugated
ienes, and diene-conjugated hydroperoxides. However, all
hese markers are considered rather unreliable, and studies
n their specificity have always given conflicting results
26–29).
High oral doses of ASA (1,000 mg) have been recently
uggested for probing ˙OH in patients (17,30). The method
s based on the ability of ˙OH to attack the benzene ring of
romatic molecules, such as ASA, and to produce stable,
ong-lasting hydroxylated compounds (Fig. 1) (16,17). For a
adical probing technique to be reliable in vivo, it is
ecessary that: 1) the probe has a sufficiently high concen-
ration (in relation to its rate constant for ˙OH) to be able to
ompete with other scavenger molecules; 2) the hydroxy-
ated product(s) cannot be further metabolized; and 3) the
roduct(s) hydroxylated by ˙OH is (are) different from
ossible enzyme-produced hydroxylated metabolites. It
hould be noted that the probing technique herein em-
loyed satisfies all three criteria owing to the very high,
iffusion-controlled rate constant of salicylate with ˙OH
1.2  1010 mol/l1 s1). 2,3-DHBA is not further
etabolized but undergoes renal clearance. Unlike 2,5-
HBA, 2,3-DHBA is not the product of any enzymatic
al Infarction (Group 2, n  74)
Group 2Ai Group 2Bi
Entry Discharge Entry Discharge
30  7 22  5* 28  6 19  4*
5.0  1.1 4.1  0.9* 5.2  1.2 3.9  1.1*
1.6  0.7 1  0.4* 1.5  0.4 0.9  0.2*
E adjusted for total cholesterol and coenzyme Q10 values significantly decreased at
was not different between patients without (Group 2Ai) and those with (Group 2Bi)
Group 2
(n  74) p Value* p Value† p Value‡
37  15 0.002 0.04 NS
2,090  1,082 0.003 0.02 NS
3,278  1,510 0.005 0.05 NS
42  78 0.001§ 0.005§ NS§
1,224  1,079 0.001 0.001 NS
hitney U test. All tested cytokines were significantly increased in Group 2 compared
for a definition of Controls, Group 1, and Group 2.
ctor-alpha receptor I; sTNFR-II  soluble tumor necrosis factor-alpha receptor II;cardi
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Oxidative Stress Status and Post-MI HF June 2, 2004:2000–8rocess in vivo. So far, intravenous administration of ASA
s a radical trap in patients (31)—an ideal approach for an
cute condition such as MI—has never been employed in
umans. Our data provide evidence that ASA can be safely
sed intravenously in humans at therapeutic doses as a
adical probing agent, and this finding is important for
urther research in this field.
The application of this technique to our patient popula-
ion indicates that the acute phase of MI (first 24 to 48 h
rom symptom onset) is invariably associated with increased
OH generation, whose degree is not related to the exten-
ion of myocardial necrosis or to the progression to HF,
hereas ˙OH generation at peak is significantly inversely
orrelated with the percentage of vitamin E decrease during
igure 4. Levels of 2,3-dihydroxybenzoic acid (DHBA)/salicylic acid (SA)
tratified by cytokine values. Group 2 patients showing high levels of tumor
ecrosis factor-alpha (TNF-a) and its soluble receptors (sTNFR-I and
TNFR-II) displayed significantly increased 2,3-DHBA/SA values at
ischarge, as compared with patients with low levels. Open bars  below
edian; solid bars  above median. *p  0.05; †p  0.01. IL 
nterleukin.
igure 5. Levels of 2,3-dihydroxybenzoic acid (DHBA)/salicylic acid (SA)
t six months, according to heart failure status. At month 6, 2,3-
HBA/SA (expressed as molar ratio 1,000) in patients with heart failure
Group 2Bii) was significantly higher than that of patients without heart
iailure (Group 2Ai). *p  0.0001.ospitalization. This would suggest that a decrease in
itamin E levels during hospitalization is a marker for
ngoing oxidative stress in Group 2 patients, indicating that
ntioxidant reserve is being eroded during MI.
Antioxidant status could not differentiate patients with
rom those without HF in our study. This could reflect that
ntioxidant mechanisms are redundant in humans (32) and
re likely to be differently affected.
Although peak oxidative stress was not correlated to the
ccurrence of HF, patients with HF as a complication of
I show a persistent elevation of ˙OH during hospitaliza-
ion and at six-month follow-up. Furthermore, we were
nable to find any LV ejection fraction threshold at dis-
harge or six months, which could significantly differentiate
OH generation in patients, irrespective of HF signs or
ymptoms. This would suggest that the degree of OSS in
ost-MI patients does not simply reflect LV systolic per-
ormance, as suggested (33), it could also reflect the inter-
lay between cardiac function and the periphery (33,34).
It is thought that TNF-alpha is involved in the patho-
enesis and progression of HF at both the central and
eripheral levels. Levels of TNF-alpha are significantly
levated in patients with HF and exert a prognostic role
ndependent of LV performance and clinical status (35).
The ROS are downstream products of TNF-alpha–
ediated signal transduction (36). It has been shown that
NF-alpha induces ROS generation in cardiac myocytes
nd peripheral muscles, and pretreatment with antioxidants
bolishes TNF-alpha–induced cellular effects (37). Simi-
arly, transgenic mice with cardiac-specific overexpression of
NF-alpha show increased ˙OH generation by myocytes
38). Furthermore, ROS can sensitize cardiac myocytes to
NF-alpha–induced apoptosis through FLICE inhibitory
rotein (FLIP) expression modulation (39). Thus, there
ight be a two-way interaction between increased ROS
eneration and TNF-alpha activity in HF: the former is
ncreased as a consequence of elevated TNF-alpha levels in
art, whereas, at the same time, the latter is positively
odulated in the setting of an altered cellular redox status.
herefore, increased TNF-alpha activity and ROS genera-
ion could play a synergic role in the progression to HF in
atients with MI.
Our data show that patients with high levels of TNF-
lpha and related soluble receptors also have increased ˙OH
eneration at both discharge and follow-up, suggesting a
ink between the two pathologic phenomena.
Interestingly, it has recently been shown that secretion of
NF-alpha by TNF-alpha–converting enzyme (TACE),
ather than transmembrane TNF-alpha, is responsible for
he dilated cardiomyopathic phenotype in mice with
ardiac-restricted overexpression of TNF-alpha (40). The
ndings that ROS can directly upregulate TACE activity
41) and subsequently increase TNF-alpha shedding pro-
ide a new working hypothesis on the TNF-alpha/ROS
nteraction in the pathogenesis and progression of HF.
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June 2, 2004:2000–8 Oxidative Stress Status and Post-MI HFtudy limitations. Firstly, in the setting of HF, increased
OS production may arise from different enzymatic
ources, including xanthine oxidase (42), mitochondria (43),
yclooxygenase, nitric oxide synthase, and nonphagocytic
AD(P)H oxidase (44). We did not investigate the possible
ource(s) of increased ˙OH generation in patients with HF,
s this was not the aim of the current study.
Secondly, we cannot exclude that ASA infusion itself
ould have partially affected absolute levels of inflammatory
ytokines.
Finally, even though not at a significant level, the pro-
ortion of smokers in Group 2 was tendentially higher than
hat in Group 1 and Controls. This could be a possible
onfounder in our study. However, to specifically address
hether smoking status could affect OSS and inflammatory
tatus in our groups, we compared smokers versus non-
mokers in Groups 1 and 2, and we could not find any
ifferences in any of the recorded parameters. Furthermore,
he proportion of smokers in Group 2a did not differ with
espect to that in Group 2b (66% vs. 75%, p  NS).
onclusions. Our data provide evidence for a distinct
attern of ˙OH generation in post-MI patients showing
rogression to HF, with a persistent increase of ˙OH
roduction in the subacute and chronic phases in patients
ith an uncomplicated post-MI course. The finding that
atients with HF display elevation of both ROS and
TNFR suggests that the interplay between OSS and
nflammatory status should be specifically targeted as a
ossible mechanism for progression to LV dysfunction
fter MI.
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